To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells
This is an interventional study of vaccination related to infection with varicella zoster virus. We will enroll participants of two age groups. Cohort 1 will be persons between the ages of 30-40; Cohort 2 will be persons who are 70 years of age or older. All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
50
All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
University of Washington Virology Research Clinic
Seattle, Washington, United States
Level of gE-specific IgG in serum.
Units will be optical density at 492 nanometers from ELISA.
Time frame: up to 1 year after vaccination
Level of gE-specific CD4 T cells in blood
Units will be cells per million CD4+ T cells in blood.
Time frame: up to 1 year after vaccination
Cytokine profile of gE-specific CD4 T cells in blood
Units will be percent of gE-reactive T cells expressing single T cell cytokines or combinations of cytokines
Time frame: up to 1 year after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.